Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma

Trupti Vardam-Kaur, Latha B. Pathangey, Daniel J. McCormick, P. Leif Bergsagel, Peter A. Cohen, Sandra J. Gendler

Research output: Contribution to journalArticlepeer-review


Multiple Myeloma (MM) patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses. Here we evaluate the possibility of adoptive cell transfer (ACT) by generating ex vivo T cells from peripheral blood mononuclear cells (PBMCs) isolated from MM patients by employing our previously devised protocols. We designed peptides from antigens (Ags) including cancer testis antigens (CTAs) that are over expressed in MM. We exposed PBMCs from different healthy donors (HDs) to single peptides. We observed reproducible Ag-specific cluster of differentiation 4+ (CD4+) and CD8+ T cell responses on exposure of PBMCs to different single peptide sequences. These peptide sequences were used to compile four different peptide cocktails. Naïve T cells from PBMCs from MM patients or HDs recognized the cognate Ag in all four peptide cocktails, leading to generation of multiclonal Ag-specific CD4+ and CD8+ effector and central memory T (TEM and TCM, respectively) cells which produced interferon-gamma (IFN-γ), granzyme B and perforin on secondary restimulation. Furthermore, this study demonstrated that immune cells from MM patients are capable of switching metabolic programs to induce effector and memory responses. Multiple peptides and cocktails were identified that induce IFN-γ+, T1-type, metabolically active T cells, thereby paving the way for feasibility testing of ACT in phase I clinical trials.

Original languageEnglish (US)
Pages (from-to)2051-2067
Number of pages17
Issue number20
StatePublished - Sep 28 2021


  • CD4/CD8 T cells
  • Cellular therapy
  • Immunotherapy
  • Multiple myeloma
  • Peptides

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this